correlation of before and after invasive breast cancer neoadjuvant chemotherapy for nfkb, cyclin d1, and survivin expression

Background objective: patients undergoing neoadjuvant chemotherapy (nc) for invasive breast cancer (ibc) therapy need biomarkers to track their progress. because of the relationship between nfkb, survivin, and cyclin d1 with nc resistance, the different expression levels of each of these biomarkers can be different between pre- and post-nc in ibc. however, no research has examined the correlation between these biomarkers before and after the nc expression. this study aimed to determine the correlation among them.methods: biomarkers expression (low and high) was used to classify 30 samples. er, pr, her2, ki-67 status, tumor grade, age, and nc response were assessed. the amounts of survivin, cyclin d1, and nfkb were evaluated using immunohistochemistry, and samples were classified based on the cut-off. chi-square and linear regression were used to evaluate the data.results: no significant association was found with the changes in the expression of survivin, cyclin d1, and nfkb, both before and after the nc. significant moderate correlations were shown between before and after the nc survivin expression (r = 0.513) and cyclin d1 expression (r = 0.543). the correlation between expression of nfkb before and after the nc was not significant.conclusion: the high potential of these proteins as prognostic indicators was demonstrated by the strong positive association between the expression of survivin and cyclin d1 before and after the nc. this upregulation of biomarkers indicates chemoresistance in developing ibc in the presence of nc.